Tag: AstraZeneca
AstraZeneca Licenses Novel Lung Cancer Drug Zegfrovy in $1.5B Global Deal
AstraZeneca announced a exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a highly differentiated, oral irreversible EGFR inhibitor designed for targeted lung cancer...
AstraZeneca Advances Oral GLP-1 Elecoglipron to Phase III Programme
AstraZeneca announced positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an investigational oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). The data,...
FDA Approves Datroway for Metastatic Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo announced that the US Food and Drug Administration (FDA) has approved Datroway(datopotamab deruxtecan) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC)...